Schrodinger, Inc. (SDGR)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 54,759 | 59,551 | 35,290 | 47,334 |
| Software Products And Services | 13,029 | - | - | - |
| Drug Discovery | 15,572 | - | - | - |
| Total cost of revenues | 28,601 | 28,427 | 17,562 | 15,999 |
| Gross profit | 26,158 | 31,124 | 17,728 | 31,335 |
| Sales and marketing | 10,734 | 10,367 | 10,349 | 9,693 |
| Research and development | 43,138 | 45,844 | 50,977 | 50,835 |
| General and administrative | 25,189 | 25,802 | 24,824 | 23,536 |
| Total operating expenses | 79,061 | 82,013 | 86,150 | 84,064 |
| Loss from operations | -52,903 | -50,889 | -68,422 | -52,729 |
| Change in fair value | - | - | 25,459 | -5,833 |
| Other income | 5,438 | 4,204 | 4,737 | 4,598 |
| Gain on equity investments | - | - | - | - |
| Change in fair value of equity investments | 4,579 | -13,095 | - | - |
| Total other income (expense) | 10,017 | -8,891 | 30,196 | -1,235 |
| Loss before income taxes | -42,886 | -59,780 | -38,226 | -53,964 |
| Income tax expense | 287 | 28 | -90 | 83 |
| Net loss | -43,173 | -59,808 | -38,136 | -54,047 |
| Net loss per share of common and limited common stockholders, basic (in usd per share) | -0.59 | -0.82 | -0.52 | -0.74 |
| Net loss per share of common and limited common stockholders, diluted (in usd per share) | -0.59 | -0.82 | -0.52 | -0.74 |
| Weighted average shares used to compute net loss per share of common and limited common stockholders, basic (in shares) | 73,427,635 | 73,057,916 | 72,813,006 | 72,711,685 |
| Weighted average shares used to compute net loss per share of common and limited common stockholders, diluted (in shares) | 73,427,635 | 73,057,916 | 72,813,006 | 72,711,685 |